Who is sponsoring NCT00692926?

NCT00692926 is sponsored by Joanne Kurtzberg, MD.

What condition does NCT00692926 study?

NCT00692926 studies MDS, Anemia, Aplastic, Inborn Errors of Metabolism, Congenital Marrow Failure, Congenital Immunodeficiency Syndrome.

What drugs are being tested in NCT00692926?

Interventions: ALDHbr Umbilical Cord Blood Cells.

What is the status of NCT00692926?

NCT00692926 is currently COMPLETED.

Last reviewed 2017-06-27 · How we verify

A Pilot Trial of Unrelated Umbilical Cord Blood Transplantation Augmented With Ex Vivo CytokinePrimed ALDHbr Umbilical Cord Blood Cells

NCT00692926 Phase 1 COMPLETED

The main purpose of this investigational (not approved by the FDA) Phase I research is to test whether transplantation of umbilical cord blood cells can be safely supplemented with a transfusion of a portion of these cells that have been sorted (collected from a special machine called a cell sorter) and then either infused a few hours after the standard transplant or for some patients grown in a special system in the laboratory prior to the transplant, designed to increase the number of stem cells transplanted. This system is currently in the early phases of testing.

Details

Lead sponsor	Joanne Kurtzberg, MD
Phase	Phase 1
Status	COMPLETED
Enrolment	37
Start date	2005-10
Completion	2012-07

Conditions

MDS
Anemia, Aplastic
Inborn Errors of Metabolism
Congenital Marrow Failure
Congenital Immunodeficiency Syndrome

Interventions

ALDHbr Umbilical Cord Blood Cells

Primary outcomes

To assess the safety of infusing ex vivo cytokine-primed ALDHbr cells isolated from banked unrelated umbilical cord blood (CB) into patients also receiving a standard unmanipulated unrelated CB transplant delivering >2.5x10e7 nucleated cells per kg. — Prospective

Countries

United States